Identificación de medicamentos intravenosos potencialmente irritantes

Lv, 2020, The incidence and risk of infusion phlebitis with peripheral intravenous catheters: A meta-analysis, J Vasc Access., 21, 342, 10.1177/1129729819877323 Wallis, 2014, Risk factors for peripheral intravenous catheter failure: A multivariate analysis of data from a randomized controlled trial, Infect Control Hosp Epidemiol., 35, 63, 10.1086/674398 Simin, 2019, Incidence, severity and risk factors of peripheral intravenous cannula-induced complications: An observational prospective study, J Clin Nurs., 28, 1585, 10.1111/jocn.14760 Mandal, 2019, Study on incidence of phlebitis following the use of peripheral intravenous catheter, J Family Med Prim Care., 8, 2827, 10.4103/jfmpc.jfmpc_559_19 2004 Milutinović, 2015, Fatores de risco para flebite: estudo com questionário sobre a percepção dos enfermeiros, Rev Lat Am., 23, 677, 10.1590/0104-1169.0192.2603 Aizpuru Martínez, 2021 Kokotis, 1998, Preventing chemical phlebitis, Nursing., 28, 41, 10.1097/00152193-199811000-00021 Manrique-Rodríguez, 2021, Standardization and chemical characterization of intravenous therapy in adult patients: A step further in medication safety, Drugs R D., 21, 39, 10.1007/s40268-020-00329-w Pérez Melgarejo, 2011, Flebitis postinfusión en catéteres venosos periféricos: una actualización del arte, Horiz Enferm., 22, 37, 10.7764/Horiz_Enferm.22.2.37 Plan Nacional de Resistencia a Antibióticos. Prevención de complicaciones relacionadas con accesos vasculares de inserción periférica. Programa Flebitis Zero. Ministerio de Sanidad, Consumo y Bienestar social. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS); 2019 [consultado 26 Ene 2021]. Disponible en: http://www.resistenciaantibioticos.es/es/system/files/content_images/programa_flebitis_zero.pdf Garate, 2015 Nicotera, 2011, La flebite associata alla terapia endovenosa/infusionale [Phlebitis associated to intravenous/infusional therapy], Assist Inferm Ric., 30, 34 Oragano, 2019, Phlebitis in intravenous amiodarone administration: Incidence and contributing factors, Crit Care Nurse., 39, e1, 10.4037/ccn2019381 Bruniera, 2015, The use of vancomycin with its therapeutic and adverse effects: A review, Eur Rev Med Pharmacol Sci., 19, 694 Meng, 2018, Association between continuous peripheral i.v. infusion of 3% sodium chloride injection and phlebitis in adults, Am J Health Syst Pharm., 75, 284, 10.2146/ajhp161028 Gorski, 2015, Intermittently delivered IV medication and pH: Reevaluating the evidence, J Infus Nurs., 38, 27, 10.1097/NAN.0000000000000081 Kuwahara, 1999, Experimental infusion phlebitis: tolerance pH of peripheral veins, J Toxicol Sci., 24, 113, 10.2131/jts.24.113 Stranz, 2005, The implications of osmolality, osmolarity and pH in infusion therapy, INS Annual Conference., 1 Stranz, 2002, A review of pH and osmolarity, Int J Pharm Compd., 6, 216 Maki, 1991, Risk factors for infusion-related phlebitis with small peripheral venous catheters. A randomized controlled trial, Ann Intern Med., 114, 845, 10.7326/0003-4819-114-10-845 Piper, 2018, The mechanistic causes of peripheral intravenous catheter failure based on a parametric computational study, Sci Rep., 8, 3441, 10.1038/s41598-018-21617-1 Grupo de trabajo de la Guía de Práctica Clínica sobre Terapia Intravenosa con Dispositivos no Permanentes en Adultos. Guía de Práctica Clínica sobre Terapia Intravenosa con Dispositivos no Permanentes en Adultos. Ministerio de Sanidad, Servicios Sociales e Igualdad. Agencia de Evaluación de Tecnologías Sanitarias de Andalucía (AETSA); 2014. Guías de Práctica Clínica en el SNS [consultado el 26 Ene 2021]. Disponible en: https://portal.guiasalud.es/wp-content/uploads/2018/12/GPC_541_Terapia_intravenosa_AETSA_compl.pdf Maklin, 2003, Phlebitis, Am J Nurs., 103, 55, 10.1097/00000446-200302000-00027